BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
BioAge Labs, Inc.NASDAQ: BIOA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $22.25M (cash outflow) rose 72.1% year over year, ahead of the +26.6% change in trailing-twelve-month net income. Sequentially, it fell 14.2% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.
Context
- Net income amounted to 896.1% of revenue in FY2025.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$93.4M (+15.9%) for the fiscal year ending Dec 2026, a step up from the +13.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.25M-14.2% QoQ
- Last fiscal yearDec 2025
- -$80.61M+13.4% YoY
- LTMMar 2026
- -$89.93M+26.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +72.1% | +29.3% | -42.8 pp |
| 1 year | +13.4% | +15.9% | +2.5 pp |
| 3-year CAGR | +26.6% | +4.3% | -22.3 pp |
| 5-year CAGR | +4.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (80.61M) USD
- Year-over-year change
- -13.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (80.61M) | -13.4% |
| FY2024 | 2024-12-31 | (71.11M) | -11.4% |
| FY2023 | 2023-12-31 | (63.85M) | -60.8% |
| FY2022 | 2022-12-31 | (39.72M) | — |
Net Income vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +26.6% is the 2nd highest of 9, against a peer median of -28.7%.
- Net income amounts to 871.8% of revenue for BIOA, versus a peer median of 66.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$286.21M CAD | -52.6% | -50.8% | 91.6% | |
| LTM Mar 2026 | $175.43M USD | +38.4% | +46.9% | — | |
| LTM Mar 2026 | $173.76M USD | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $169.52M USD | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $108.95M USD | -56.6% | -10.1% | 281.6% | |
| LTM Mar 2026 | $97.59M USD | +25.7% | +50.6% | 4840.8% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $89.93M USD | +26.6% | +26.6% | 871.8% |
| LTM Mar 2026 | CA$58.58M CAD | -507.7% | -39.5% | 18.8% | |
| LTM Mar 2026 | $34.09M USD | — | -30.8% | 25.2% | |
| LTM Mar 2026 | $17.17M USD | -26.3% | -28.6% | 41.1% | |
| Peer median (excluding BIOA) | — | -28.7% | -16.9% | 66.4% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.